NCT03650218 is a NA clinical trial of THIODERM STRONG in Correction of Nasolabial Folds, sponsored by Croma-Pharma GmbH.

Who is sponsoring NCT03650218?

NCT03650218 is sponsored by Croma-Pharma GmbH.

What drugs are being tested in NCT03650218?

Interventions in NCT03650218: THIODERM STRONG.

What condition does NCT03650218 study?

NCT03650218 studies Correction of Nasolabial Folds.

Is NCT03650218 still recruiting?

NCT03650218 is currently completed. Last updated 9 December 2024.

Last reviewed 2024-12-09 · How we verify

NCT03650218

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Effectiveness of THIODERM STRONG in the Correction of Nasolabial Folds

Completed NA Last updated 9 December 2024

What this trial tests

NA trial testing THIODERM STRONG in Correction of Nasolabial Folds in 74 participants. Completed in 23 December 2019.

Timeline

10 July 2018

Primary endpoint
23 December 2019

23 December 2019

Quick facts

Lead sponsor	Croma-Pharma GmbH
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	74
Start date	10 July 2018
Primary completion	23 December 2019
Estimated completion	23 December 2019
Sites	2 locations across Austria

Drugs / interventions tested

THIODERM STRONG

Conditions studied

Correction of Nasolabial Folds — all drugs for Correction of Nasolabial Folds →

Sponsor

Croma-Pharma GmbH — full company profile →

Who can join

18 and older, any sex, with Correction of Nasolabial Folds. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, open label, dose-escalating, multicenter clinical investigation to evaluate the safety and effectiveness of THIODERM STRONG in the correction of nasolabial folds. The performance is assessed using the 5-point Nasolabial Folds Severity Rating Scale (NLF-SRS) at Week 12 compared to baseline.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Croma-Pharma GmbH trials

Trials by the same sponsor.

NCT07492277 — A Non-Interventional PMCF Study Evaluating Croma Revitalis for the Correction of Fine Lines · recruiting
NCT07475455 — Filler Post Market Survey (FIPS) · active not recruiting
NCT06135337 — THIODERM ELATE for Augmentation of Very Thin, Thin, and Moderately Thick Lips · NA · completed
NCT06128109 — THIODERM STRONG Compared to Juvéderm® VOLUMA® Lidocaine for the Treatment of Midface Volume Deficit · NA · completed
NCT05386030 — Saypha® VOLUME Lidocaine for Midface Augmentation · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03650218 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Croma-Pharma GmbH
Last refreshed: 9 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03650218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing